XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

Interleukin-1β (IL-1β) is a potent mediator of inflammatory responses and plays a role in the differentiation of a number of lymphoid cells. In several inflammatory and autoimmune diseases, serum levels of IL-1β are elevated and correlate with disease development and severity. The central role of the IL-1 pathway in several diseases has been validated by inhibitors currently in clinical development or approved by the FDA. However, the need to effectively modulate IL-1β-mediated local inflammation with the systemic delivery of an efficacious, safe and convenient drug still exists. To meet these challenges, we developed XOMA 052 (gevokizumab), a potent anti-IL-1β neutralizing antibody that was designed in silico and humanized using Human Engineering™ technology. XOMA 052 has a 300 femtomolar binding affinity for human IL-1β and an in vitro potency in the low picomolar range. XOMA 052 binds to a unique IL-1β epitope where residues critical for binding have been identified. We have previously reported that XOMA 052 is efficacious in vivo in a diet-induced obesity mouse model thought to be driven by low levels of chronic inflammation. We report here that XOMA 052 also reduces acute inflammation in vivo, neutralizing the effect of exogenously administered human IL-1β and blocking peritonitis in a mouse model of acute gout. Based on its high potency, novel mechanism of action, long half-life, and high affinity, XOMA 052 provides a new strategy for the treatment of a number of inflammatory, autoimmune and metabolic diseases in which the role of IL-1β is central to pathogenesis.

[1]  M. Donath,et al.  Blockade of interleukin 1 in type 1 diabetes mellitus , 2010, Nature Reviews Endocrinology.

[2]  A. Solinger,et al.  Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. , 2005, Arthritis and rheumatism.

[3]  P. Larsen,et al.  Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity , 2010, The Journal of Biological Chemistry.

[4]  S. Shire.  Current trends in monoclonal antibody development and manufacturing , 2010 .

[5]  陈刚,et al.  IL-1β binding antibodies and fragments , 2006 .

[6]  B. Brandhuber,et al.  Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1β , 1997, Nature.

[7]  Dirk E. Smith,et al.  The IL-1 family: regulators of immunity , 2010, Nature Reviews Immunology.

[8]  P. Hawkins,et al.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.

[9]  L. Roskos,et al.  Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. , 2005, Biochemical and biophysical research communications.

[10]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[11]  S. Abramson,et al.  Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. , 2002, Rheumatology.

[12]  K. Maedler,et al.  XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model. , 2010, Endocrinology.

[13]  L. Joosten,et al.  The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis , 2008, Arthritis research & therapy.

[14]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[15]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[16]  A. Abbas,et al.  Role of interleukin 1 in the activation of T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  G. Kersley.  European League Against Rheumatism , 1951 .

[18]  Egil Lien,et al.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.

[19]  H. Joller-jemelka,et al.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.

[20]  S. Dower,et al.  IL-1 induces rapid phosphorylation of the IL-1 receptor. , 1989, Journal of immunology.

[21]  A. Schmitz,et al.  A mutational analysis of receptor binding sites of interleukin-1β:differences in binding of human interleukin-1β muteins to human and mouse receptors , 1994 .

[22]  L. Punzi,et al.  Pro-inflammatory interleukins in the synovial fluid of rheumatoid arthritis associated with joint hypermobility. , 2001, Rheumatology.

[23]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[24]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[25]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[26]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[27]  S. Malozowski,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[28]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[29]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[30]  K. Mills,et al.  A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis , 2006, The Journal of experimental medicine.

[31]  C. Dinarello.  The many worlds of reducing interleukin-1. , 2005, Arthritis and rheumatism.

[32]  K. Murphy,et al.  Th17: an effector CD4 T cell lineage with regulatory T cell ties. , 2006, Immunity.

[33]  C. Dinarello,et al.  Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. , 1998, International reviews of immunology.

[34]  G. Studnicka,et al.  Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. , 1994, Protein engineering.

[35]  K. Mills,et al.  Immune modulation: IL-1, master mediator or initiator of inflammation , 2009, Nature Medicine.

[36]  P. Katsamba,et al.  Analyzing a kinetic titration series using affinity biosensors. , 2006, Analytical biochemistry.

[37]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.